Parish L C, Jungkind D L
Department of Dermatology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
Am J Med. 1991 Dec 30;91(6A):115S-119S. doi: 10.1016/0002-9343(91)90322-o.
Temafloxacin is an investigational fluoroquinolone with in vitro activity against common skin pathogens and a favorable pharmacokinetic profile. A randomized, double-blind, multicenter study was conducted in 492 patients to compare the safety and efficacy of temafloxacin 600 mg with ciprofloxacin 750 mg for the treatment of bacterial infections of the skin or skin structure. Both drugs were given twice daily for 7-28 days. The most common diagnoses were abscess and superficial skin infection, which were usually caused by staphylococci. In evaluable patients, clinical success (cure plus improvement) rates were 96% in the temafloxacin group and 99% in the ciprofloxacin group. Bacteriologic eradication rates were 95% and 93% in the temafloxacin and ciprofloxacin groups, respectively. Both regimens were well tolerated. Temafloxacin appears to be safe and effective for the management of bacterial infections of the skin and skin structure.
替马沙星是一种正在研究的氟喹诺酮类药物,具有体外抗常见皮肤病原体的活性和良好的药代动力学特征。对492例患者进行了一项随机、双盲、多中心研究,以比较600毫克替马沙星与750毫克环丙沙星治疗皮肤或皮肤结构细菌感染的安全性和有效性。两种药物均每日给药两次,疗程7 - 28天。最常见的诊断为脓肿和浅表皮肤感染,通常由葡萄球菌引起。在可评估的患者中,替马沙星组的临床成功率(治愈加改善)为96%,环丙沙星组为99%。替马沙星组和环丙沙星组的细菌清除率分别为95%和93%。两种治疗方案耐受性均良好。替马沙星似乎对治疗皮肤和皮肤结构的细菌感染安全有效。